CQDM. We do it.
During the breast cancer awareness month, CQDM is proud to announce its participation in the clinical design project for a new targeted and personalized treatment against Sortilin-positive triple negative breast cancers.
The research team of Dr. Borhane Annabi at the UQAM | Université du Québec à Montréal, in collaboration with the Theratechnologies Inc. team, has developed a new targeted therapy for the treatment of TNBC by targeting and exploiting the functions of cecilin in the internalization of its drug TH1902. This receptor, highly expressed on the surface of breast cancer cells, as well as in various other gynecological cancers including ovarian cancer and endometrial cancer, is an extremely important player in the rapid internalization processes of large molecules. This allows TH902 to be rapidly internalized into cancer cells and metastasis cells.
Published preclinical results indicated that this new anticancer molecule conjugated to docetaxel (TH1902) would exhibit improved efficacy and specificity, while having few side effects compared to current therapeutic treatments. Phase 1 clinical trials are underway, and these advances will give more hope to patients with these types of cancers.
This project was carried out in collaboration with the Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE), the Canadian Cancer Society, the Quebec Breast Cancer Foundation, and Theratechnologies Inc.
Learn more about the project by clicking here.
Do you have a research project and would be interested in funding it effectively? Please click this link.
to learn how to do it with our CQDM team. The next deadline to receive the projects is November 8, 2023.